Technical Analysis for SNPX - Synaptogenix, Inc.
Grade | Last Price | % Change | Price Change |
---|---|---|---|
F | 4.65 | -0.64% | -0.03 |
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Strong | Down | Down | Down |
Date | Alert Name | Type | % Chg |
---|---|---|---|
50 DMA Resistance | Bearish | 0.00% | |
20 DMA Support | Bullish | 0.00% | |
Bollinger Band Squeeze | Range Contraction | 0.00% | |
NR7 | Range Contraction | 0.00% | |
Down 3 Days in a Row | Weakness | 0.00% | |
Gapped Down | Weakness | 0.00% | |
50 DMA Resistance | Bearish | -0.64% | |
20 DMA Support | Bullish | -0.64% | |
Bollinger Band Squeeze | Range Contraction | -0.64% | |
Inside Day | Range Contraction | -0.64% |
Alert | Time |
---|---|
Possible NR7 | about 8 hours ago |
20 DMA Resistance | about 10 hours ago |
10 DMA Support | about 11 hours ago |
20 DMA Support | about 12 hours ago |
60 Minute Opening Range Breakout | about 12 hours ago |
Get a Trading Sidekick!
- Earnings date: 02/28/2024
Synaptogenix, Inc. Description
Synaptogenix is a clinical-stage biopharmaceutical company that has historically worked to develop novel therapies for neurodegenerative diseases. Synaptogenix has conducted clinical and preclinical studies of its lead therapeutic candidate, Bryostatin-1, in Alzheimer's disease. Preclinical studies have also demonstrated Bryostatin's regenerative mechanisms of action for the rare disease, Fragile X syndrome, and for other neurodegenerative disorders such as multiple sclerosis, stroke, and traumatic brain injury. The U.S. Food and Drug Administration has granted Orphan Drug Designation to Synaptogenix for Bryostatin-1 as a treatment for Fragile X syndrome. Bryostatin-1 has already undergone testing in more than 1,500 people in cancer studies, thus creating a large safety data base that will further inform clinical trial designs.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Cancer Biology Neuroscience Rare Diseases Alzheimer's Disease Stroke Multiple Sclerosis Neurodegenerative Diseases Amyotrophic Lateral Sclerosis Neurodegeneration Neurodegenerative Disorders Fragile X Syndrome Traumatic Brain Injury
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 47.0 |
52 Week Low | 3.5275 |
Average Volume | 51,589 |
200-Day Moving Average | 7.60 |
50-Day Moving Average | 4.73 |
20-Day Moving Average | 4.64 |
10-Day Moving Average | 4.69 |
Average True Range | 0.49 |
RSI (14) | 49.75 |
ADX | 31.35 |
+DI | 20.00 |
-DI | 12.57 |
Chandelier Exit (Long, 3 ATRs) | 4.47 |
Chandelier Exit (Short, 3 ATRs) | 5.68 |
Upper Bollinger Bands | 5.00 |
Lower Bollinger Band | 4.27 |
Percent B (%b) | 0.52 |
BandWidth | 15.73 |
MACD Line | 0.00 |
MACD Signal Line | -0.02 |
MACD Histogram | 0.0227 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 5.03 | ||||
Resistance 3 (R3) | 5.02 | 4.90 | 4.96 | ||
Resistance 2 (R2) | 4.90 | 4.80 | 4.90 | 4.94 | |
Resistance 1 (R1) | 4.77 | 4.74 | 4.84 | 4.78 | 4.92 |
Pivot Point | 4.65 | 4.65 | 4.68 | 4.65 | 4.65 |
Support 1 (S1) | 4.52 | 4.55 | 4.59 | 4.53 | 4.38 |
Support 2 (S2) | 4.40 | 4.49 | 4.40 | 4.36 | |
Support 3 (S3) | 4.27 | 4.40 | 4.34 | ||
Support 4 (S4) | 4.28 |